141 related articles for article (PubMed ID: 30981729)
1. N-Glycoproteomics of Patient-Derived Xenografts: A Strategy to Discover Tumor-Associated Proteins in High-Grade Serous Ovarian Cancer.
Sinha A; Hussain A; Ignatchenko V; Ignatchenko A; Tang KH; Ho VWH; Neel BG; Clarke B; Bernardini MQ; Ailles L; Kislinger T
Cell Syst; 2019 Apr; 8(4):345-351.e4. PubMed ID: 30981729
[TBL] [Abstract][Full Text] [Related]
2. Targeted Mass Spectrometry of Longitudinal Patient Sera Reveals LTBP1 as a Potential Surveillance Biomarker for High-Grade Serous Ovarian Carcinoma.
Wenk D; Khan S; Ignatchenko V; May T; Bernardini MQ; Kislinger T
J Proteome Res; 2024 Feb; 23(2):749-759. PubMed ID: 38266179
[TBL] [Abstract][Full Text] [Related]
3. A combination of molecular and clinical parameters provides a new strategy for high-grade serous ovarian cancer patient management.
Bradbury M; Borràs E; Vilar M; Castellví J; Sánchez-Iglesias JL; Pérez-Benavente A; Gil-Moreno A; Santamaria A; Sabidó E
J Transl Med; 2022 Dec; 20(1):611. PubMed ID: 36544142
[TBL] [Abstract][Full Text] [Related]
4. Expression of serum human epididymal secretory protein E4 at low grade and high grade serous carcinomas.
Zhu YF; He LS; Zhang ZD; Huang QS
Asian Pac J Trop Med; 2012 Dec; 5(12):925-30. PubMed ID: 23199707
[TBL] [Abstract][Full Text] [Related]
5. A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer.
Salminen L; Nadeem N; Jain S; Grènman S; Carpén O; Hietanen S; Oksa S; Lamminmäki U; Pettersson K; Gidwani K; Huhtinen K; Hynninen J
Gynecol Oncol; 2020 Mar; 156(3):689-694. PubMed ID: 31889528
[TBL] [Abstract][Full Text] [Related]
6. Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma.
Hu Y; Pan J; Shah P; Ao M; Thomas SN; Liu Y; Chen L; Schnaubelt M; Clark DJ; Rodriguez H; Boja ES; Hiltke T; Kinsinger CR; Rodland KD; Li QK; Qian J; Zhang Z; Chan DW; Zhang H;
Cell Rep; 2020 Oct; 33(3):108276. PubMed ID: 33086064
[TBL] [Abstract][Full Text] [Related]
7. Discovery of serum biomarkers implicated in the onset and progression of serous ovarian cancer in a rat model using iTRAQ technique.
Huang Y; Zhang X; Jiang W; Wang Y; Jin H; Liu X; Xu C
Eur J Obstet Gynecol Reprod Biol; 2012 Nov; 165(1):96-103. PubMed ID: 22818854
[TBL] [Abstract][Full Text] [Related]
8. Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice.
De Haven Brandon A; Box G; Hallsworth A; Court W; Matthews N; Herodek B; Arteagabeitia AB; Valenti M; Kirkin V
Sci Rep; 2020 Jul; 10(1):10799. PubMed ID: 32612269
[TBL] [Abstract][Full Text] [Related]
9. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
10. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
11. An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors.
Li QK; Shah P; Tian Y; Hu Y; Roden RBS; Zhang H; Chan DW
Clin Proteomics; 2017; 14():16. PubMed ID: 28491011
[TBL] [Abstract][Full Text] [Related]
12. Altered expression of sialylated glycoproteins in ovarian cancer sera using lectin-based ELISA assay and quantitative glycoproteomics analysis.
Wu J; Xie X; Nie S; Buckanovich RJ; Lubman DM
J Proteome Res; 2013 Jul; 12(7):3342-52. PubMed ID: 23731285
[TBL] [Abstract][Full Text] [Related]
13. Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients.
Wei BR; Hoover SB; Ross MM; Zhou W; Meani F; Edwards JB; Spehalski EI; Risinger JI; Alvord WG; Quiñones OA; Belluco C; Martella L; Campagnutta E; Ravaggi A; Dai RM; Goldsmith PK; Woolard KD; Pecorelli S; Liotta LA; Petricoin EF; Simpson RM
PLoS One; 2009 Oct; 4(10):e7670. PubMed ID: 19888321
[TBL] [Abstract][Full Text] [Related]
14. Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
Harrington BS; He Y; Davies CM; Wallace SJ; Adams MN; Beaven EA; Roche DK; Kennedy C; Chetty NP; Crandon AJ; Flatley C; Oliveira NB; Shannon CM; deFazio A; Tinker AV; Gilks CB; Gabrielli B; Brennan DJ; Coward JI; Armes JE; Perrin LC; Hooper JD
Br J Cancer; 2016 Feb; 114(4):417-26. PubMed ID: 26882065
[TBL] [Abstract][Full Text] [Related]
15. Glycoproteomics-based signatures for tumor subtyping and clinical outcome prediction of high-grade serous ovarian cancer.
Pan J; Hu Y; Sun S; Chen L; Schnaubelt M; Clark D; Ao M; Zhang Z; Chan D; Qian J; Zhang H
Nat Commun; 2020 Dec; 11(1):6139. PubMed ID: 33262351
[TBL] [Abstract][Full Text] [Related]
16. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
17. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
[TBL] [Abstract][Full Text] [Related]
18. A Robust and Versatile Automated Glycoanalytical Technology for Serum Antibodies and Acute Phase Proteins: Ovarian Cancer Case Study.
O'Flaherty R; Muniyappa M; Walsh I; Stöckmann H; Hilliard M; Hutson R; Saldova R; Rudd PM
Mol Cell Proteomics; 2019 Nov; 18(11):2191-2206. PubMed ID: 31471495
[TBL] [Abstract][Full Text] [Related]
19. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma.
Diamandis EP; Scorilas A; Fracchioli S; Van Gramberen M; De Bruijn H; Henrik A; Soosaipillai A; Grass L; Yousef GM; Stenman UH; Massobrio M; Van Der Zee AG; Vergote I; Katsaros D
J Clin Oncol; 2003 Mar; 21(6):1035-43. PubMed ID: 12637468
[TBL] [Abstract][Full Text] [Related]
20. Glycoproteins and glycoproteomics in pancreatic cancer.
Pan S; Brentnall TA; Chen R
World J Gastroenterol; 2016 Nov; 22(42):9288-9299. PubMed ID: 27895417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
